• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

作者信息

Tandstad Torgrim, Kollmannsberger Christian K, Roth Bruce J, Jeldres Claudio, Gillessen Silke, Fizazi Karim, Daneshmand Siamak, Lowrance William T, Hanna Nasser H, Albany Costantine, Foster Richard, Cedermark Gabriella Cohn, Feldman Darren R, Powles Thomas, Lewis Mark A, Grimison Peter Scott, Bank Douglas, Porter Christopher, Albers Peter, De Santis Maria, Srinivas Sandy, Bosl George J, Nichols Craig R

机构信息

Torgrim Tandstad, St Olavs University Hospital, Trondheim, Norway; Christian K. Kollmannsberger, University of British Columbia, Vancouver, British Columbia, Canada; Bruce J. Roth, Washington University School of Medicine, St Louis, MO; Claudio Jeldres, Sherbrooke University, Sherbrooke, Quebec, Canada; Silke Gillessen, Kantonsspital, St Gallen, Switzerland; Karim Fizazi, University of Paris Sud, Paris, France; Siamak Daneshmand, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA; William T. Lowrance, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Nasser H. Hanna, Indiana University School of Medicine, Indianapolis, IN; Gabriella Cohn Cedermark, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Darren R. Feldman, Memorial Sloan Kettering Cancer Center and Weill Medical Cornell Medical College, New York, NY; Thomas Powles, Barts Cancer Institute, St Bartholomew's Hospital, Queen Mary University of London, London, United Kingdom; Mark A. Lewis, Intermountain Health, Salt Lake City, UT; Peter Scott Grimison, University of Sydney, Sydney, New South Wales, Australia; Douglas Bank, Testicular Cancer Resource Center, Riverwoods, IL; Christopher Porter, Virginia Mason Medical Center, Seattle, WA; Peter Albers, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; Maria De Santis, Cancer Research Center, University of Warwick, Coventry, United Kingdom; Sandy Srinivas, Stanford University School of Medicine, Stanford, CA; George J. Bosl, Memorial Sloan Kettering Cancer Center, New York, NY; and Craig R. Nichols, Precision Genomics Cancer Research Clinic, Intermountain Health, Salt Lake City, UT; Testicular Cancer Commons, Portland, OR.

出版信息

J Clin Oncol. 2017 Nov 1;35(31):3525-3528. doi: 10.1200/JCO.2017.73.4723. Epub 2017 Aug 30.

DOI:10.1200/JCO.2017.73.4723
PMID:28854068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5791831/
Abstract
摘要

相似文献

1
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.熟能生巧：睾丸癌作为可治愈肿瘤模型的故事续篇。
J Clin Oncol. 2017 Nov 1;35(31):3525-3528. doi: 10.1200/JCO.2017.73.4723. Epub 2017 Aug 30.
2
[Diagnosis and therapy of testicular tumors].[睾丸肿瘤的诊断与治疗]
Urologe A. 2002 Jul;41(4):374-85; quiz 386-7. doi: 10.1007/s00120-002-0219-x.
3
Treatment options for patients with stage I nonseminomatous testis cancer: it's all good.I期非精原细胞瘤性睾丸癌患者的治疗选择：效果都不错。
Eur Urol. 2011 Apr;59(4):563-5. doi: 10.1016/j.eururo.2011.01.012. Epub 2011 Jan 18.
4
[Therapy of germ cell tumors. Model for interdisciplinary treatment approach].[生殖细胞肿瘤的治疗。跨学科治疗方法模型]
Med Klin (Munich). 1996 Apr 12;91 Suppl 3:80-4.
5
A third option in the management of patients with clinical stage I nonseminomatous germ cell tumor?临床I期非精原细胞瘤性生殖细胞肿瘤患者管理的第三种选择？
J Clin Oncol. 1990 Jan;8(1):4-8. doi: 10.1200/JCO.1990.8.1.4.
6
[Germ cell tumors of the testis].[睾丸生殖细胞肿瘤]
Wien Klin Wochenschr. 1994;106(2):37-44.
7
[Testicular tumors--a curable disease?].[睾丸肿瘤——一种可治愈的疾病？]
Schweiz Rundsch Med Prax. 1988 May 17;77(20):560-4.
8
Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience.临床I期睾丸肿瘤的监测与辅助治疗——综述及瑞典睾丸癌研究组（SWENOTECA）的经验
Andrology. 2015 Jan;3(1):102-10. doi: 10.1111/andr.280. Epub 2014 Oct 1.
9
[Once fatal, now curable!].[曾经致命，如今可治！]
Laeknabladid. 2011 Mar;97(3):141. doi: 10.17992/lbl.2011.03.353.
10
Editorial Comment to Clinical characteristics and survival outcomes of elderly patients with de novo metastatic germ cell tumors.关于初发性转移性生殖细胞肿瘤老年患者的临床特征及生存结局的社论评论
Int J Urol. 2024 Jul;31(7):812. doi: 10.1111/iju.15525. Epub 2024 Jun 28.

引用本文的文献

1
Global trends in testicular and prostate cancer among adolescents and young adult males aged 15-49 years, 1990-2021: insights from the GBD study.1990年至2021年15至49岁青少年及青年男性睾丸癌和前列腺癌的全球趋势：来自全球疾病负担研究的见解
Sci Rep. 2025 Jul 2;15(1):23388. doi: 10.1038/s41598-025-07361-3.
2
High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed or refractory testicular cancer: a systematic review and meta-analysis.大剂量化疗作为复发或难治性睾丸癌患者的初始挽救化疗：一项系统评价和荟萃分析。
Front Oncol. 2024 Oct 1;14:1437574. doi: 10.3389/fonc.2024.1437574. eCollection 2024.
3
SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023).SEOM-GG 临床指南：睾丸生殖细胞肿瘤的管理（2023 年）。
Clin Transl Oncol. 2024 Nov;26(11):2783-2799. doi: 10.1007/s12094-024-03532-2. Epub 2024 Jul 3.
4
Trends in the global, regional, and national burden of testicular cancer from 1990 to 2019: an observational study with 30-year global data.全球、地区和国家睾丸癌负担的趋势：1990 年至 2019 年的观察性研究，有 30 年的全球数据。
Int J Surg. 2024 Aug 1;110(8):4633-4647. doi: 10.1097/JS9.0000000000001603.
5
Single-cell multi-omics analysis of human testicular germ cell tumor reveals its molecular features and microenvironment.单细胞多组学分析人类睾丸生殖细胞肿瘤揭示其分子特征和微环境。
Nat Commun. 2023 Dec 20;14(1):8462. doi: 10.1038/s41467-023-44305-9.
6
Radiomics and Clinicopathological Characteristics for Predicting Lymph Node Metastasis in Testicular Cancer.用于预测睾丸癌淋巴结转移的影像组学和临床病理特征
Cancers (Basel). 2023 Nov 29;15(23):5630. doi: 10.3390/cancers15235630.
7
Integrated Microarray-Based Data Analysis of miRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours.基于集成微阵列的 miRNA 表达谱数据分析：鉴定顺铂耐药的睾丸生殖细胞肿瘤的新型生物标志物。
Int J Mol Sci. 2023 Jan 27;24(3):2495. doi: 10.3390/ijms24032495.
8
Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center.在一家三级转诊中心进行腹膜后淋巴结清扫术治疗睾丸癌的 20 年经验。
Medicina (Kaunas). 2023 Jan 10;59(1):133. doi: 10.3390/medicina59010133.
9
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study.单疗程博来霉素、依托泊苷和顺铂（1xBEP）作为睾丸非精原细胞瘤临床1期的辅助治疗：一项基于人群研究的结果、安全性及复发风险因素
Ther Adv Med Oncol. 2022 Mar 31;14:17588359221086813. doi: 10.1177/17588359221086813. eCollection 2022.
10
Narrative review of developing new biomarkers for decision making in advanced testis cancer.关于开发用于晚期睾丸癌决策的新生物标志物的叙述性综述。
Transl Androl Urol. 2021 Oct;10(10):4075-4084. doi: 10.21037/tau-20-1246.

本文引用的文献

1
Patterns of performance of retroperitoneal lymph node dissections by American urologists: most retroperitoneal lymph node dissections in the United States are performed by low-volume surgeons.美国泌尿外科医生进行腹膜后淋巴结清扫术的情况：在美国，大多数腹膜后淋巴结清扫术是由手术量少的外科医生完成的。
Urology. 2014 Dec;84(6):1325-8. doi: 10.1016/j.urology.2014.07.054. Epub 2014 Oct 11.
2
Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience.临床I期睾丸肿瘤的监测与辅助治疗——综述及瑞典睾丸癌研究组（SWENOTECA）的经验
Andrology. 2015 Jan;3(1):102-10. doi: 10.1111/andr.280. Epub 2014 Oct 1.
3
Monitoring the delivery of cancer care: Commission on Cancer and National Cancer Data Base.癌症护理服务监测：癌症委员会与国家癌症数据库
Surg Oncol Clin N Am. 2012 Jul;21(3):377-88, vii. doi: 10.1016/j.soc.2012.03.005. Epub 2012 Apr 17.
4
Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.德国睾丸癌研究组进行的AUO试验AH 01/94：一项随机III期试验，比较腹膜后淋巴结清扫术与博来霉素、依托泊苷联合顺铂化疗一个疗程在临床I期非精原性睾丸生殖细胞肿瘤辅助治疗中的效果。
J Clin Oncol. 2008 Jun 20;26(18):2966-72. doi: 10.1200/JCO.2007.12.0899. Epub 2008 May 5.
5
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party.治疗机构对“预后不良”转移性非精原细胞瘤患者生存的影响。欧洲癌症研究与治疗组织泌尿生殖系统癌症协作组及医学研究理事会睾丸癌工作组。
J Natl Cancer Inst. 1999 May 19;91(10):839-46. doi: 10.1093/jnci/91.10.839.
6
Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer.规模重要吗？转移性睾丸癌的治疗患者数量与患者预后之间的关联。
J Natl Cancer Inst. 1999 May 19;91(10):816-8. doi: 10.1093/jnci/91.10.816.
7
Management of malignant teratoma: does referral to a specialist unit matter?恶性畸胎瘤的管理：转诊至专科单位重要吗？
Lancet. 1993 Apr 17;341(8851):999-1002. doi: 10.1016/0140-6736(93)91082-w.
8
After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer.治疗取得突破后：晚期睾丸癌试验数据与基于人群的数据比较
J Clin Oncol. 1994 Feb;12(2):368-77. doi: 10.1200/JCO.1994.12.2.368.
9
Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture.睾丸癌作为可治愈肿瘤的模型：理查德与欣达·罗森塔尔基金会奖讲座
Cancer Res. 1981 Sep;41(9 Pt 1):3275-80.
10
Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.未经选择的非精原细胞转移性睾丸癌患者的预后因素：一项多中心研究经验
J Clin Oncol. 1991 May;9(5):818-26. doi: 10.1200/JCO.1991.9.5.818.